abacavir Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals carbocyclic nucleosides 34 136470-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • 1592U89
  • abacavir
  • abacavir sulfate
  • ziagen
  • abacavir succinate
a carbocyclic nucleoside with potent selective anti-HIV activity; structure given in first source
  • Molecular weight: 286.34
  • Formula: C14H18N6O
  • CLOGP: 0.81
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 101.88
  • ALOGS: -2.37
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 77 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.20 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 29.93 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 83 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.84 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 8, 1999 EMA
Dec. 17, 1998 FDA VIIV HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 753.21 20.27 405 10423 107807 46567427
Abortion spontaneous 414.52 20.27 202 10626 43444 46631790
Foetal exposure during pregnancy 321.13 20.27 152 10676 30595 46644639
Virologic failure 300.06 20.27 74 10754 1981 46673253
Viral mutation identified 295.64 20.27 72 10756 1827 46673407
Live birth 291.02 20.27 104 10724 10226 46665008
Maternal exposure during pregnancy 213.31 20.27 182 10646 102367 46572867
Drug resistance 212.84 20.27 96 10732 17272 46657962
Pathogen resistance 209.11 20.27 71 10757 5989 46669245
Lipodystrophy acquired 208.67 20.27 52 10776 1453 46673781
Immune reconstitution inflammatory syndrome 205.13 20.27 69 10759 5656 46669578
Foetal growth restriction 162.10 20.27 60 10768 6507 46668727
Abortion induced 152.55 20.27 65 10763 10195 46665039
Premature baby 145.60 20.27 75 10753 18037 46657197
Hypomania 141.96 20.27 49 10779 4339 46670895
Jaundice cholestatic 139.18 20.27 50 10778 4979 46670255
Hepatotoxicity 128.15 20.27 77 10751 24932 46650302
Stillbirth 112.90 20.27 46 10782 6445 46668789
Blood HIV RNULL increased 111.77 20.27 27 10801 660 46674574
Schizophrenia 110.14 20.27 49 10779 8519 46666715
Foetal death 106.01 20.27 48 10780 8695 46666539
Caesarean section 103.29 20.27 58 10770 16545 46658689
Treatment noncompliance 101.64 20.27 71 10757 29660 46645574
Pregnancy 93.22 20.27 65 10763 27072 46648162
Acoustic stimulation tests abnormal 84.55 20.27 16 10812 113 46675121
Supernumerary nipple 83.69 20.27 15 10813 75 46675159
Psychotic disorder 77.25 20.27 54 10774 22567 46652667
Congenital naevus 75.74 20.27 16 10812 208 46675026
Blood bilirubin increased 75.65 20.27 63 10765 34121 46641113
Hyperbilirubinaemia 74.68 20.27 40 10788 10398 46664836
CD4 lymphocytes decreased 72.17 20.27 23 10805 1587 46673647
Low set ears 71.68 20.27 16 10812 273 46674961
Premature labour 68.99 20.27 39 10789 11260 46663974
Premature delivery 64.64 20.27 48 10780 22021 46653213
Drug interaction 60.01 20.27 140 10688 202954 46472280
Viral load increased 58.99 20.27 19 10809 1356 46673878
Fall 57.94 20.27 5 10823 329092 46346142
Drug ineffective 57.78 20.27 44 10784 677794 45997440
Hepatic enzyme increased 57.19 20.27 82 10746 81705 46593529
HIV infection 55.53 20.27 15 10813 578 46674656
Drug reaction with eosinophilia and systemic symptoms 52.36 20.27 48 10780 29500 46645734
Ectopic pregnancy 50.79 20.27 20 10808 2562 46672672
Mitochondrial cytopathy 49.64 20.27 12 10816 294 46674940
Gastroschisis 48.42 20.27 11 10817 204 46675030
Mitochondrial toxicity 48.14 20.27 12 10816 335 46674899
Oligohydramnios 47.88 20.27 24 10804 5441 46669793
Cholelithiasis 46.68 20.27 51 10777 38630 46636604
Trisomy 21 46.30 20.27 12 10816 393 46674841
HIV-associated neurocognitive disorder 46.01 20.27 10 10818 150 46675084
Fanconi syndrome acquired 44.08 20.27 14 10814 955 46674279
Twin pregnancy 41.36 20.27 14 10814 1167 46674067
Placental insufficiency 39.72 20.27 14 10814 1317 46673917
Left ventricular dilatation 39.52 20.27 10 10818 297 46674937
Pre-eclampsia 39.33 20.27 24 10804 7970 46667264
Cholestasis of pregnancy 38.09 20.27 13 10815 1111 46674123
Pain 37.98 20.27 33 10795 476915 46198319
Hepatocellular injury 37.50 20.27 40 10788 29482 46645752
Fatigue 36.61 20.27 53 10775 608644 46066590
Infertility 36.48 20.27 11 10817 631 46674603
Renal failure 35.34 20.27 80 10748 113514 46561720
Ovarian failure 34.14 20.27 12 10816 1120 46674114
Patent ductus arteriosus 33.94 20.27 17 10811 3845 46671389
Low birth weight baby 33.82 20.27 19 10809 5415 46669819
Renal colic 32.82 20.27 12 10816 1254 46673980
Pain in extremity 32.20 20.27 10 10818 258670 46416564
Normal newborn 32.07 20.27 19 10809 5982 46669252
Astrocytoma malignant 31.75 20.27 6 10822 42 46675192
Microcephaly 31.54 20.27 10 10818 678 46674556
Jaundice 31.31 20.27 36 10792 28809 46646425
Ultrasound scan abnormal 30.44 20.27 8 10820 277 46674957
Drug-induced liver injury 29.82 20.27 33 10795 25335 46649899
Eosinophilia 29.80 20.27 29 10799 19188 46656046
Product substitution issue 29.75 20.27 26 10802 15005 46660229
Off label use 29.34 20.27 27 10801 379814 46295420
Lipoatrophy 28.88 20.27 8 10820 339 46674895
Dermatitis exfoliative generalised 28.67 20.27 14 10814 2999 46672235
Breast disorder 27.79 20.27 12 10816 1939 46673295
Arthralgia 26.89 20.27 27 10801 364576 46310658
Mental disability 26.47 20.27 6 10822 110 46675124
Peripheral swelling 26.21 20.27 3 10825 158068 46517166
Pleocytosis 25.71 20.27 8 10820 510 46674724
Hepatic necrosis 25.48 20.27 16 10812 5585 46669649
Cervix operation 25.09 20.27 4 10824 8 46675226
Placenta praevia 24.98 20.27 9 10819 902 46674332
Retroplacental haematoma 24.86 20.27 6 10822 146 46675088
Antiviral drug level below therapeutic 24.78 20.27 5 10823 51 46675183
Acute hepatic failure 24.31 20.27 23 10805 14698 46660536
Central nervous system lesion 23.95 20.27 19 10809 9596 46665638
Pubertal failure 23.69 20.27 4 10824 13 46675221
Premature rupture of membranes 23.62 20.27 14 10814 4409 46670825
Small for dates baby 23.41 20.27 13 10815 3624 46671610
Ocular icterus 23.40 20.27 13 10815 3627 46671607
Alpha 1 foetoprotein abnormal 23.39 20.27 5 10823 69 46675165
Insulin resistance 23.38 20.27 8 10820 689 46674545
Product size issue 23.27 20.27 7 10821 398 46674836
Maxillonasal dysplasia 23.25 20.27 4 10824 15 46675219
HIV wasting syndrome 23.04 20.27 4 10824 16 46675218
Nasopharyngitis 23.01 20.27 4 10824 153994 46521240
Generalised anxiety disorder 22.96 20.27 10 10818 1650 46673584
Vomiting 22.82 20.27 181 10647 452613 46222621
Rash 22.24 20.27 150 10678 356362 46318872
Portal vein thrombosis 22.10 20.27 11 10817 2456 46672778
Proteinuria 22.03 20.27 23 10805 16530 46658704
Hemiataxia 21.70 20.27 4 10824 24 46675210
Aqueductal stenosis 21.70 20.27 4 10824 24 46675210
Foetal heart rate disorder 21.55 20.27 5 10823 102 46675132
Bronchopulmonary dysplasia 21.33 20.27 6 10822 269 46674965
Genotype drug resistance test positive 21.17 20.27 7 10821 543 46674691
Delayed puberty 21.11 20.27 5 10823 112 46675122
Spinal cord injury 21.07 20.27 7 10821 551 46674683
Amenorrhoea 20.93 20.27 17 10811 8878 46666356
Renal tubular dysfunction 20.74 20.27 6 10822 298 46674936
Social avoidant behaviour 20.64 20.27 11 10817 2828 46672406
Developmental coordination disorder 20.59 20.27 4 10824 33 46675201
Urinary tract infection 20.36 20.27 13 10815 220253 46454981
AIDS related complication 20.28 20.27 4 10824 36 46675198

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 586.57 13.09 182 22686 3378 29926232
Immune reconstitution inflammatory syndrome 582.94 13.09 230 22638 8871 29920739
Virologic failure 392.68 13.09 131 22737 3088 29926522
Mitochondrial toxicity 313.36 13.09 104 22764 2410 29927200
Progressive external ophthalmoplegia 287.70 13.09 83 22785 1183 29928427
Viral mutation identified 246.96 13.09 88 22780 2538 29927072
Foetal exposure during pregnancy 220.95 13.09 200 22668 36671 29892939
Eyelid ptosis 185.89 13.09 87 22781 5101 29924509
Blood HIV RNULL increased 142.84 13.09 50 22818 1366 29928244
Pathogen resistance 133.41 13.09 82 22786 8328 29921282
Diplopia 118.21 13.09 92 22776 13680 29915930
Polydactyly 114.65 13.09 41 22827 1194 29928416
Drug resistance 114.23 13.09 106 22762 20027 29909583
HIV infection 109.65 13.09 43 22825 1625 29927985
Drug interaction 97.69 13.09 354 22514 199214 29730396
Lipoatrophy 96.08 13.09 30 22838 567 29929043
Fanconi syndrome acquired 93.48 13.09 41 22827 2062 29927548
Nephrolithiasis 90.51 13.09 103 22765 24707 29904903
Viral load increased 87.46 13.09 43 22825 2811 29926799
Dyslipidaemia 78.70 13.09 51 22817 5676 29923934
Hypertriglyceridaemia 78.09 13.09 58 22810 8040 29921570
Renal impairment 73.07 13.09 183 22685 84001 29845609
HIV-associated neurocognitive disorder 71.47 13.09 21 22847 320 29929290
Hyperbilirubinaemia 69.84 13.09 75 22793 16867 29912743
Hyperlipidaemia 68.97 13.09 68 22800 13839 29915771
Nephropathy toxic 68.16 13.09 60 22808 10579 29919031
Renal tubular disorder 67.37 13.09 44 22824 4962 29924648
Osteonecrosis 65.76 13.09 71 22797 16064 29913546
Ophthalmoplegia 59.84 13.09 26 22842 1278 29928332
Hepatitis C 58.95 13.09 61 22807 13144 29916466
Exposure during pregnancy 56.88 13.09 51 22817 9210 29920400
Off label use 55.84 13.09 65 22803 249225 29680385
Drug ineffective 53.25 13.09 113 22755 340274 29589336
Extraocular muscle paresis 53.11 13.09 18 22850 445 29929165
Fanconi syndrome 52.18 13.09 26 22842 1749 29927861
Fall 51.84 13.09 38 22830 181834 29747776
Pneumonia 50.61 13.09 113 22755 334193 29595417
Mycobacterium avium complex infection 49.64 13.09 29 22839 2682 29926928
Meningitis cryptococcal 48.95 13.09 26 22842 1998 29927612
Cachexia 47.88 13.09 40 22828 6571 29923039
Anal cancer 46.16 13.09 16 22852 424 29929186
Kaposi's sarcoma 45.55 13.09 20 22848 1008 29928602
Hypotension 45.19 13.09 52 22816 200513 29729097
Mitochondrial cytopathy 44.12 13.09 13 22855 200 29929410
Pyrexia 43.74 13.09 378 22490 294111 29635499
Cytomegalovirus chorioretinitis 42.21 13.09 28 22840 3240 29926370
Jaundice 42.13 13.09 83 22785 32403 29897207
Oesophageal candidiasis 40.24 13.09 30 22838 4180 29925430
Retinal toxicity 39.90 13.09 14 22854 385 29929225
Blood triglycerides increased 39.37 13.09 51 22817 13966 29915644
Death 39.12 13.09 141 22727 357142 29572468
CD4 lymphocytes decreased 37.52 13.09 22 22846 2048 29927562
Proteinuria 36.67 13.09 53 22815 16092 29913518
Syphilis 36.63 13.09 13 22855 370 29929240
Acquired immunodeficiency syndrome 36.44 13.09 14 22854 500 29929110
Atrial fibrillation 35.73 13.09 19 22849 108105 29821505
Oral candidiasis 35.43 13.09 43 22825 11028 29918582
Tubulointerstitial nephritis 35.31 13.09 55 22813 17836 29911774
Progressive multifocal leukoencephalopathy 33.84 13.09 38 22830 8975 29920635
White matter lesion 33.40 13.09 14 22854 629 29928981
Drug-induced liver injury 33.39 13.09 59 22809 21215 29908395
Mitochondrial myopathy 33.35 13.09 10 22858 164 29929446
Amniotic band syndrome 33.32 13.09 7 22861 22 29929588
Multiple-drug resistance 32.77 13.09 23 22845 2918 29926692
Calculus urinary 32.65 13.09 17 22851 1254 29928356
Lactic acidosis 32.61 13.09 73 22795 31140 29898470
Drug abuse 32.58 13.09 11 22857 82061 29847549
Premature baby 32.50 13.09 51 22817 16640 29912970
CSF HIV escape syndrome 32.31 13.09 9 22859 112 29929498
Hepatotoxicity 32.00 13.09 53 22815 18092 29911518
Taeniasis 30.77 13.09 8 22860 75 29929535
Completed suicide 30.70 13.09 19 22849 99473 29830137
Renal colic 29.95 13.09 18 22850 1754 29927856
Treatment noncompliance 29.74 13.09 62 22806 25191 29904419
Facial wasting 29.55 13.09 9 22859 156 29929454
Febrile neutropenia 29.45 13.09 23 22845 106670 29822940
Liver disorder 29.37 13.09 68 22800 29654 29899956
HIV viraemia 29.06 13.09 8 22860 95 29929515
Drug reaction with eosinophilia and systemic symptoms 29.06 13.09 66 22802 28422 29901188
HIV associated nephropathy 28.99 13.09 10 22858 261 29929349
Osteoporosis 28.71 13.09 38 22830 10625 29918985
Immune reconstitution inflammatory syndrome associated tuberculosis 28.09 13.09 11 22857 414 29929196
Enterovirus infection 27.88 13.09 12 22856 576 29929034
Primary syphilis 27.85 13.09 6 22862 22 29929588
Oesophageal atresia 26.92 13.09 11 22857 463 29929147
Malignant neoplasm progression 26.49 13.09 11 22857 72276 29857334
Chronic hepatitis C 26.35 13.09 11 22857 489 29929121
Blood pressure increased 26.27 13.09 11 22857 71917 29857693
Hyperplasia adrenal 26.12 13.09 5 22863 8 29929602
Encephalitis 25.65 13.09 28 22840 6408 29923202
Hypercholesterolaemia 25.13 13.09 30 22838 7562 29922048
Portal hypertension 25.12 13.09 22 22846 3851 29925759
Bacterial pyelonephritis 25.10 13.09 9 22859 264 29929346
Disease progression 24.99 13.09 15 22853 79859 29849751
Dyspnoea 24.90 13.09 151 22717 333144 29596466
Hypermetabolism 24.87 13.09 8 22860 167 29929443
Renal hypoplasia 24.78 13.09 7 22861 92 29929518
Venolymphatic malformation 24.75 13.09 6 22862 41 29929569
Small for dates baby 24.46 13.09 20 22848 3188 29926422
Renal disorder 24.45 13.09 55 22813 23529 29906081
Drug level decreased 24.44 13.09 26 22842 5779 29923831
Lymphadenopathy 24.33 13.09 56 22812 24320 29905290
Acute myocardial infarction 24.15 13.09 92 22776 52847 29876763
Hepatosplenomegaly 23.96 13.09 21 22847 3680 29925930
HIV peripheral neuropathy 23.92 13.09 6 22862 48 29929562
Pain 23.92 13.09 61 22807 172580 29757030
Pneumocystis jirovecii pneumonia 23.73 13.09 45 22823 17075 29912535
Trisomy 21 23.70 13.09 10 22858 457 29929153
Hemivertebra 23.68 13.09 7 22861 109 29929501
Hyperlactacidaemia 23.64 13.09 18 22850 2588 29927022
Diabetes mellitus 23.60 13.09 78 22790 41787 29887823
Cardiac failure congestive 23.53 13.09 18 22850 84389 29845221
Neonatal asphyxia 23.46 13.09 9 22859 320 29929290
Hepatic cirrhosis 23.35 13.09 43 22825 15956 29913654
Hypersensitivity 23.10 13.09 92 22776 53936 29875674
Renal failure 23.09 13.09 173 22695 128793 29800817
Hepatic enzyme decreased 23.01 13.09 6 22862 57 29929553
Alpha 1 foetoprotein increased 22.58 13.09 11 22857 704 29928906
Cerebral toxoplasmosis 22.44 13.09 14 22854 1458 29928152
Oropharyngeal candidiasis 22.11 13.09 11 22857 737 29928873
Tuberculosis 22.07 13.09 29 22839 8048 29921562
Musculoskeletal toxicity 21.97 13.09 6 22862 69 29929541
Rash 21.78 13.09 233 22635 191656 29737954
Constipation 21.58 13.09 33 22835 112873 29816737
Periarthritis 21.52 13.09 12 22856 1015 29928595
Glycosuria 21.34 13.09 13 22855 1298 29928312
Haemophilic arthropathy 21.33 13.09 7 22861 156 29929454
Myalgia 21.27 13.09 115 22753 76552 29853058
Crystal urine 21.23 13.09 6 22862 79 29929531
Choroiditis 20.97 13.09 11 22857 824 29928786
Confusional state 20.78 13.09 45 22823 134789 29794821
Myocardial infarction 20.53 13.09 165 22703 125460 29804150
Lymphadenitis 20.45 13.09 14 22854 1706 29927904
Blood bilirubin increased 20.41 13.09 68 22800 36568 29893042
Nervous system disorder 20.19 13.09 36 22832 13033 29916577
Product use in unapproved indication 20.18 13.09 16 22852 73677 29855933
Lipohypertrophy 20.01 13.09 8 22860 318 29929292
Neuropsychiatric symptoms 19.84 13.09 9 22859 490 29929120
Anogenital warts 19.60 13.09 9 22859 504 29929106
Skin candida 19.55 13.09 9 22859 507 29929103
Insomnia 19.49 13.09 130 22738 93206 29836404
Sepsis 19.30 13.09 53 22815 146342 29783268
Erythema elevatum diutinum 19.18 13.09 4 22864 12 29929598
Pulmonary tuberculosis 19.13 13.09 21 22847 4836 29924774
Endocardial fibroelastosis 18.94 13.09 4 22864 13 29929597
Cell death 18.87 13.09 15 22853 2296 29927314
Blood insulin increased 18.83 13.09 8 22860 372 29929238
Hepatitis 18.72 13.09 48 22820 22308 29907302
Hepatic fibrosis 18.67 13.09 18 22850 3562 29926048
Chronic obstructive pulmonary disease 18.62 13.09 6 22862 46120 29883490
Hepatomegaly 18.60 13.09 30 22838 10017 29919593
Lymphoma 18.43 13.09 30 22838 10091 29919519
Pulmonary sequestration 18.35 13.09 5 22863 57 29929553
Intentional product use issue 18.15 13.09 3 22865 36437 29893173
Transplant rejection 17.74 13.09 28 22840 9178 29920432
Coccidioidomycosis 17.74 13.09 9 22859 629 29928981
CD4 lymphocytes increased 17.64 13.09 7 22861 273 29929337
Post transplant distal limb syndrome 17.64 13.09 7 22861 273 29929337
Blood lactic acid increased 17.61 13.09 22 22846 5808 29923802
Transaminases increased 17.25 13.09 48 22820 23409 29906201
Neonatal disorder 17.20 13.09 10 22858 916 29928694
Hypophosphataemia 17.18 13.09 26 22842 8219 29921391
Hepatitis A 17.11 13.09 8 22860 467 29929143
Varices oesophageal 17.10 13.09 17 22851 3492 29926118
Human immunodeficiency virus transmission 17.09 13.09 4 22864 23 29929587
Syncope 17.01 13.09 24 22844 84879 29844731
Heart transplant rejection 16.82 13.09 11 22857 1242 29928368
Long QT syndrome 16.65 13.09 14 22854 2319 29927291
Biliary colic 16.45 13.09 10 22858 994 29928616
Treatment failure 16.41 13.09 61 22807 34618 29894992
Hyperuricaemia 16.39 13.09 24 22844 7370 29922240
Psychiatric decompensation 16.34 13.09 11 22857 1304 29928306
Pancreatic failure 16.32 13.09 9 22859 745 29928865
Genital herpes 16.05 13.09 8 22860 538 29929072
Peripheral swelling 15.81 13.09 14 22854 61060 29868550
Infection 15.71 13.09 22 22846 78052 29851558
Blood uric acid increased 15.50 13.09 21 22847 6002 29923608
Blood creatinine increased 15.45 13.09 121 22747 91254 29838356
Blood alkaline phosphatase increased 15.42 13.09 56 22812 31431 29898179
Gastrointestinal haemorrhage 15.36 13.09 25 22843 83421 29846189
Hepatic function abnormal 15.26 13.09 68 22800 41877 29887733
Reversible ischaemic neurological deficit 15.24 13.09 4 22864 39 29929571
Congenital pigmentation disorder 15.24 13.09 3 22865 6 29929604
Epistaxis 15.15 13.09 11 22857 52970 29876640
Cardiac arrest 15.13 13.09 30 22838 92820 29836790
Neurotoxicity 15.09 13.09 32 22836 13150 29916460
Sleep disorder 15.05 13.09 47 22821 24432 29905178
CD4 lymphocytes abnormal 15.05 13.09 5 22863 116 29929494
Cardio-respiratory arrest 15.00 13.09 13 22855 57293 29872317
Foetal growth restriction 14.99 13.09 16 22852 3569 29926041
Amoebiasis 14.98 13.09 4 22864 42 29929568
Segmented hyalinising vasculitis 14.89 13.09 4 22864 43 29929567
Ophthalmic herpes simplex 14.83 13.09 6 22862 246 29929364
Foetal death 14.83 13.09 6 22862 246 29929364
Testicular mass 14.81 13.09 5 22863 122 29929488
CSF virus identified 14.81 13.09 4 22864 44 29929566
Psoriasis 14.73 13.09 7 22861 42499 29887111
Abnormal dreams 14.70 13.09 24 22844 8091 29921519
Contusion 14.67 13.09 3 22865 31277 29898333
Hepatitis D 14.65 13.09 4 22864 46 29929564
Pancytopenia 14.59 13.09 113 22755 84939 29844671
Thrombosis 14.57 13.09 7 22861 42224 29887386
Nausea 14.50 13.09 312 22556 296645 29632965
Skin test negative 14.49 13.09 4 22864 48 29929562
Genotype drug resistance test positive 14.47 13.09 11 22857 1578 29928032
Retinal telangiectasia 14.38 13.09 3 22865 9 29929601
Foetal monitoring abnormal 14.38 13.09 3 22865 9 29929601
Haematocrit decreased 14.28 13.09 3 22865 30696 29898914
Hallucination 14.27 13.09 10 22858 49049 29880561
Foetal cystic hygroma 14.14 13.09 3 22865 10 29929600
Viral load decreased 14.13 13.09 4 22864 53 29929557
Cushingoid 13.91 13.09 13 22855 2474 29927136
Spine malformation 13.84 13.09 5 22863 150 29929460
Congenital ureterocele 13.72 13.09 3 22865 12 29929598
Herpes virus infection 13.66 13.09 13 22855 2531 29927079
Aspartate aminotransferase increased 13.63 13.09 89 22779 63333 29866277
International normalised ratio increased 13.53 13.09 10 22858 47729 29881881
VACTERL syndrome 13.34 13.09 3 22865 14 29929596
Hepatitis D RNULL positive 13.17 13.09 3 22865 15 29929595
Rash maculo-papular 13.12 13.09 46 22822 25372 29904238

Pharmacologic Action:

SourceCodeDescription
ATC J05AF06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC J05AR02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR13 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175459 Nucleoside Analog
FDA EPC N0000175462 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
CHEBI has role CHEBI:36044 anti-virus drug
CHEBI has role CHEBI:53756 reverse transcriptase inhibitor
CHEBI has role CHEBI:88188 allergenic drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Toxic amblyopia contraindication 965003
Myositis contraindication 26889001 DOID:633
Hepatic failure contraindication 59927004
Pancreatitis contraindication 75694006 DOID:4989
Large liver contraindication 80515008
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Disorder of muscle contraindication 129565002 DOID:423
Steatosis of liver contraindication 197321007
Acute pancreatitis contraindication 197456007 DOID:2913
Chronic pancreatitis contraindication 235494005
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Hypertriglyceridemia contraindication 302870006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
HLA-B 5701 Positive Status contraindication
Drug Resistance to Anti-retroviral Therapy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.09 acidic
pKa2 5.64 Basic
pKa3 0.88 Basic
pKa4 0.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR EC50 5.28 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein EC50 5.28 WOMBAT-PK

External reference:

IDSource
WR2TIP26VS UNII
4029879 VUID
N0000180961 NUI
D00891 KEGG_DRUG
168146-84-7 SECONDARY_CAS_RN
C0540137 UMLSCUI
CHEBI:421707 CHEBI
1KX PDB_CHEM_ID
CHEMBL2106686 ChEMBL_ID
CHEMBL4303288 ChEMBL_ID
CHEMBL1380 ChEMBL_ID
CHEMBL1200619 ChEMBL_ID
441300 PUBCHEM_CID
DB01048 DRUGBANK_ID
7544 INN_ID
C106538 MESH_SUPPLEMENTAL_RECORD_UI
11152 IUPHAR_LIGAND_ID
190521 RXNORM
14010 MMSL
191490 MMSL
30504 MMSL
66957 MMSL
7865 MMSL
d04376 MMSL
007687 NDDF
007688 NDDF
116084008 SNOMEDCT_US
387005008 SNOMEDCT_US
412074007 SNOMEDCT_US
4021139 VANDF
4024130 VANDF
4029879 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Abacavir and Lamivudine HUMAN PRESCRIPTION DRUG LABEL 2 0093-5382 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0121-0897 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0378-4105 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6523 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 0904-6874 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
Abacavir Human Prescription Drug Label 1 31722-557 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 31722-562 SOLUTION 20 mg ORAL ANDA 28 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-402 TABLET, FILM COATED 600 mg ORAL ANDA 29 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 35573-430 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Abacavir and Lamivudine HUMAN PRESCRIPTION DRUG LABEL 2 42291-115 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 49702-206 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 49702-217 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-221 TABLET, FILM COATED 300 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 49702-222 SOLUTION 20 mg ORAL NDA 26 sections
Triumeq HUMAN PRESCRIPTION DRUG LABEL 3 49702-231 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 50268-049 TABLET 300 mg ORAL ANDA 27 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 51079-204 TABLET, FILM COATED 300 mg ORAL ANDA 29 sections
Abacavir Sulfate HUMAN PRESCRIPTION DRUG LABEL 1 53808-0627 TABLET, FILM COATED 300 mg ORAL ANDA 30 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 53808-0767 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ZIAGEN HUMAN PRESCRIPTION DRUG LABEL 1 53808-0811 TABLET, FILM COATED 300 mg ORAL NDA 29 sections
TRIZIVIR HUMAN PRESCRIPTION DRUG LABEL 3 53808-0990 TABLET, FILM COATED 300 mg ORAL NDA 28 sections
EPZICOM HUMAN PRESCRIPTION DRUG LABEL 2 54868-5600 TABLET, FILM COATED 600 mg ORAL NDA 26 sections
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE HUMAN PRESCRIPTION DRUG LABEL 3 57297-286 TABLET 300 mg ORAL ANDA 29 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 64380-717 TABLET 300 1 ORAL ANDA 25 sections
Abacavir Human Prescription Drug Label 1 65862-073 TABLET, FILM COATED 300 mg ORAL ANDA 27 sections
Abacavir Human Prescription Drug Label 1 65862-089 SOLUTION 20 mg ORAL ANDA 27 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 65862-335 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Abacavir and Lamivudine Human Prescription Drug Label 2 65862-900 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Abacavir HUMAN PRESCRIPTION DRUG LABEL 1 68084-021 TABLET, FILM COATED 300 mg ORAL ANDA 28 sections
ABACAVIR, LAMIVUDINE AND ZIDOVUDINE HUMAN PRESCRIPTION DRUG LABEL 3 68180-286 TABLET 300 mg ORAL ANDA 28 sections